BLUE EARTH DIAGNOSTICS RESEARCH PARTNERSHIPS

Blue Earth Diagnostics is focused on licensing next generation radiopharmaceutical technologies from leading academic and industry institutions and applying our developmental and commercialization expertise to deliver them to clinicians who care for cancer patients.

We are looking for cutting-edge science to assemble a world-leading molecular imaging portfolio focused on addressing unmet medical needs in cancer diagnostics.

We are a recognized leader and a preferred partner, and we collaborate with world-renowned academic institutions in the field of radiopharmaceutical technologies.

UKBED-N/A-2500009 / March 2025

MRI-solo-linksbündig-mit-Schrift_Pantone-300

Technical University of Munich.

“We are pleased with the licensing of the rhPSMA technology to Scintomics and onwards to Blue Earth Diagnostics - both teams’ credentials in nuclear medicine and their track record in molecular diagnostics fit together perfectly. We are confident that our ongoing and intensive collaboration will help expedite patient access to this very exciting science.”

DR HANS JÜRGEN WESTER, Professor of Pharmaceutical Radiochemistry
DR MATTHIAS EIBER, Associate Professor, Department of Nuclear Medicine

Scintomics

Blue Earth Diagnostics acquired exclusive, worldwide rights to rhPSMA from Scintomics in 2018 to expand its portfolio and has been investigating its use as a diagnostic imaging agent.

Jan Niclas Wester, Chief Executive Officer of Scintomics GmbH remarks “We have been thoroughly impressed by the efficiency and dedication of Blue Earth Diagnostics. Their remarkable speed in getting product to market previously has given us confidence that they would ensure rhPSMA would reach patients swiftly and effectively. Our collaboration has set a new standard in the field, bringing significant advancements to cancer diagnosis.”

Philochem

Blue Earth Diagnostics and Philochem AG, have entered into a partnership for the development of an organic ligand which binds to Fibroblast Activation Protein (FAP), for applications as a diagnostic imaging agent. With a Phase 1 clinical trial completed by Philochem, Blue Earth Diagnostics will continue to develop and commercialise the tracer.

Prof. Dr. Dario Neri, Member of the Board of Philochem and CEO of the Philogen Group commented, ‘We are very excited about the results collected with our FAP imaging agent and look forward to the next steps being conducted by Blue Earth Diagnostics.’